Alphabodies cross over the boundaries between biologics and small chemical drugs
Complix NV, a biopharmaceutical company focused on the discovery and development of Alphabodies, a class of protein therapeutics that are active against both extracellular and intracellular disease targets, announces that it will provide an update on new developments with its Alphabody(TM) platform at the Biologics Partnering Forum in Boston, MA on 29 April 2012.